Life Medical Gains IDE For Repel-CV Cardiovascular Anti-Adhesion Product
This article was originally published in The Gray Sheet
Life Medical Sciences expects to have enough data gathered on its Repel-CV cardiovascular anti-adhesion product by the end of the year to support a humanitarian use device exemption.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.